buffer.

AMENDMENTS TO THE CLAIMS

1. (Currently Amended) A liquid preparation comprising 1w/w% to 20w/w% of a camptothecin derivative which is prepared by binding a compound of the formula [I]:

wherein R¹ is a substituted or unsubstituted lower alkyl group, X¹ is a group of the formula: -NHR² (where R² is a hydrogen atom or a lower alkyl group) or a hydroxy group and Alk is a straight or branched chain alkylene group optionally interrupted by an oxygen atom, and a polysaccharide having carboxyl groups via an amino acid or a peptide, or a pharmaceutically acceptable salt thereof, which is adjusted to pH 5-8 with a

- 2. (Previously Presented) The liquid preparation according to claim 1, wherein one or more compounds selected from the group consisting of citric acid, an alkali metal citrate, acetic acid, an alkali metal acetate and an alkali metal dihydrogen phosphate are used as the buffer.
- 3. (Previously Presented) The liquid preparation according to claim 2, wherein the ionic strength of the buffer is 0.2 or less than 0.2.
- 4. (Previously Presented) The liquid preparation according to any one of claims 1 to 3, wherein the pH is adjusted to 5 to 7.5.

Docket No.: 0020-5301PUS1

- 5. (Previously Presented)The liquid preparation according to any one of claims 1 to 3, wherein the pH is adjusted to 5 to 7.
- 6. (Previously Presented) The liquid preparation according to any one of claims 1 to 3, wherein the pH is adjusted to 6 to 7.

7. (Cancelled)

- 8. (Previously Presented) The liquid preparation according to claim 1, wherein one or more ingredients selected from a stabilizer and a filler are further contained therein.
- 9. (Previously Presented) The liquid preparation according to claim 1, wherein one or more stabilizers selected from an alkali metal carbonate and alkali metal hydrogen carbonate, and one or more fillers selected from lactose, sucrose, mannitol, dextran, maltose and trehalose are further contained therein.
- 10. (Previously Presented) The liquid preparation according to claim 1 wherein one or more salts selected from an alkali metal chloride, an alkaline earth metal chloride and an alkali metal sulphate are further contained therein.
- 11. (Previously Presented) The liquid preparation according to claim 1, wherein R^1 is an unsubstituted $C_{1\cdot 6}$ alkyl group, X^1 is an amino group and Alk is a straight chain $C_{1\cdot 6}$ alkylene group not interrupted by an oxygen atom, the polysaccharide is a carboxymethylated dextran or pullulan, and the peptide is a peptide consisting of 2 5 amino acids.

- 12. (Currently Amended) The liquid preparation according to claim 11, wherein R¹ is an ethyl group, and the group of the formula: X¹-Alk-O- is a 3-aminopropyloxy group, and the camptothecin compound [I] is being bound at position 10 of a camptothecin nucleus, the polysaccharide is dextran in which a carboxyl group is introduced, and the peptide is glycyl-glycyl-L- or D-phenylalanyl-glycine, glycyl-glycine, glycyl-glycyl-glycyl-glycyl-glycyl-glycyl-glycyl-glycyl-glycyl-glycyl-glycyl-glycyl-glycyl-glycyl-glycyl-glycyl-glycyl-glycyl-glycyl-glycine (SEQ ID NO: 2), L- or D-phenylalanyl-glycine, or L- or D-leucyl-glycine.
- 13. (Previously Presented) The liquid preparation according to claim 12, wherein the peptide is glycyl-glycyl-glycine.
- 14. (Previously Presented) A lyophilized drug composition prepared by lyophilizing the liquid preparation according to claim 1.
- 15. (Original) A liquid composition for injection wherein the composition according to claim 14 is dissolved in an aqueous medium.
- 16. (Currently Amended) A liquid preparation comprising <u>lw/v% to 20w/v% to 20w/w</u> of a camptothecin derivative, which is prepared by binding a compound of the formula (Ia):

$$Ra-NH(CH_2)_3-O = 0$$

$$H_5C_2$$

$$O$$

$$H_5C_2$$

$$O$$

$$O$$

$$O$$

$$O$$

wherein Ra is a hydrogen atom or a C₁₋₆ alkyl group, and a dextran having carboxylic groups via glycyl-glycyl, or a pharmaceutically acceptable salt thereof, wherein the liquid preparation is adjusted to pH 5 to 8 with a buffer.

Application No. 10/509,912

Amendment dated August 8, 2008

After Final Office Action of February 11, 2008

- 17. (Previously Presented) The liquid preparation according to claim 16, wherein the buffer is one or more compounds selected from citric acid, an alkali metal citrate, acetic acid, an alkali metal acetate and an alkali metal dihydrogen phosphate.
- 18. (Previously Presented) The liquid preparation according to claim 17, wherein the buffer is citric acid and sodium dihydrogen phosphate.
- 19. (Previously Presented) The liquid preparation according to claim 18, wherein sodium chloride is further contained therein.